Featured Articles

Roche has announced positive results from the Phase III evERA study evaluating giredestrant combined with everolimus in patients with estrogen receptor (ER)-positive, HER2-negative,…
Read More...

Roche announced that it has entered into a definitive agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company developing innovative therapies for…
Read More...

GSK plc announced plans to invest $30 billion in the United States over the next five years, focusing on research and development and supply chain infrastructure. This major investment…
Read More...

Raludotatug deruxtecan (R-DXd), a novel CDH6-targeted antibody-drug conjugate developed by Daiichi Sankyo and Merck, has received Breakthrough Therapy Designation (BTD) from the U.S.…
Read More...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Novo Nordisk’s oral diabetes drug Rybelsus (oral…
Read More...

The Chinese National Medical Products Administration (NMPA) has approved Tzield (teplizumab) as the country’s first disease-modifying therapy for autoimmune type 1 diabetes (T1D). The…
Read More...

Merck, known as MSD outside the U.S. and Canada, announced positive results from its Phase 3 STRIDE-13 trial evaluating CAPVAXIVE, its 21-valent pneumococcal conjugate vaccine, in…
Read More...

Novartis announced it has agreed to acquire Tourmaline Bio, a clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 monoclonal antibody designed to…
Read More...

AbbVie announced that Health Canada has approved ELAHERE® (mirvetuximab soravtansine for injection) under the Priority Review process. ELAHERE is an antibody-drug conjugate (ADC)…
Read More...

Gilead Sciences, Inc. announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's…
Read More...

Amgen has announced plans to invest more than $600 million in a cutting-edge center for science and innovation at its global headquarters in Thousand Oaks, California. The new facility…
Read More...

Boehringer Ingelheim announced that its drug HERNEXEOS (zongertinib tablets) has received approval from China’s National Medical Products Administration (NMPA) as a monotherapy…
Read More...

Novartis has announced encouraging results from its Phase IV V-DIFFERENCE study, which evaluated Leqvio (inclisiran) in patients with high cholesterol who had not met…
Read More...

AbbVie announced that Health Canada has granted a Notice of Compliance (NOC) for RINVOQ (upadacitinib) for the treatment of adults with giant cell arteritis (GCA). The approval includes…
Read More...

China’s National Medical Products Administration (NMPA) has approved DATROWAY (datopotamab deruxtecan) for the treatment of adults with unresectable or metastatic hormone receptor (HR)…
Read More...

Genentech, a member of the Roche Group, officially broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina, marking a major milestone as the biotech giant…
Read More...

AbbVie and Gilgamesh Pharmaceuticals have entered into a definitive agreement under which AbbVie will acquire Gilgamesh’s lead investigational candidate, bretisilocin, a next-generation…
Read More...

Eli Lilly and Company announced that its investigational oral GLP-1 receptor agonist, orforglipron, delivered significant weight loss and blood sugar control in a Phase 3 clinical trial…
Read More...

Kite, a Gilead Company, announced it will acquire Interius BioTherapeutics, a privately held biotech firm pioneering in vivo CAR therapies, in a $350 million deal aimed at advancing…
Read More...

Johnson & Johnson has announced a major expansion of its U.S. manufacturing capabilities with a $2 billion, 10-year investment in a new 160,000+ square foot facility at FUJIFILM’s…
Read More...